Methods for Two Concentration Ranges

The second example of development and validation of an analytical method for pharmacokinetic studies of a candidate compound in drug development (clinical studies) concerns an additional complication rather different from the enantiomeric distinction discussed above. In this case (Sennbro 2006) the drug candidate (laquinimod) was a synthetic compound intended for oral treatment of multiple sclerosis. In pre-clinical studies the pharmacokinetics in animal models had been determined using [Pg.660]

the time savings in the extraction-clean-up step more than made up for this. [Pg.661]

As mentioned above, many other examples of development of analytical methods, fit for purpose in either the drug discovery or drug development phases, conld have been chosen. Some of these are discussed in earlier chapters in the context of general principles of trace quantitative analysis. [Pg.661]